Top Story

IASLC: All physicians should screen patients with cancer for tobacco use

September 7, 2019
FDA News

FDA grants orphan drug status to anti-BCMA CAR T-cell therapy for multiple myeloma

September 5, 2019
The FDA has given orphan drug status to CT053, an investigational chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. CT053 (CARsgen…
In the Journals

Familial risks identified across hematologic malignancies

August 30, 2019
Individuals with a child, parent or sibling with a hematologic malignancy may be at higher risk for being diagnosed with the same disease, according to results of a…
In the Journals

Women underrepresented in leadership of oncologic randomized clinical trials

August 27, 2019
Oncologic randomized clinical trials published between 2003 and 2018 exhibited a low rate of female corresponding authorship in relation to the overall percentage of…
More Headlines »

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »

VIDEO: Triple therapy with ixazomib significantly improved PFS in patients with multiple myeloma

July 17, 2016
More »
Resource Centers
At Issue: Multiple Myeloma Resource Center

At Issue: Multiple Myeloma Resource Center